Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Chron Obstruct Pulmon Dis
Hlavní autoři: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://ncbi.nlm.nih.gov/pubmed/26543359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S90948
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky